-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I4Pw1gb8lJUbpvBT6EOsiMr2DLEkFCL64hUKyH2B48/UuYYko+y9eRwJUKghpiO4 D4yU13nSo61WKcauHhPPGQ== 0000950116-00-002911.txt : 20001220 0000950116-00-002911.hdr.sgml : 20001220 ACCESSION NUMBER: 0000950116-00-002911 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20001031 FILED AS OF DATE: 20001219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: SEC FILE NUMBER: 000-25169 FILM NUMBER: 791894 BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANA STATE: A1 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO M5J STATE: A1 10-Q/A 1 0001.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended October 31, 2000 [ ] TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . ---------------------- ---------------------- COMMISSION FILE NUMBER: 0-25169 GENEREX BIOTECHNOLOGY CORPORATION (Exact name of registrant as specified in its charter) Delaware 82-0490211 - -------------------------------- --------------------------------- (State of other jurisdiction of (IRS Employer Identification No.) incorporation or organization) 33 HARBOR SQUARE, SUITE 202 TORONTO, ONTARIO CANADA M5J 2G2 (Address of principal executive offices) 416/364-2551 (Registrant's telephone number, including area code) Not applicable - -------------------------------------------------------------------------------- (Former name, former address and former fiscal year if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No APPLICABLE ONLY TO CORPORATE ISSUERS The number of outstanding shares of the registrant's Common Stock, par value $.001, was 18,768,930 as of October 31, 2000. By this amendment, the Company hereby corrects the Consolidated Statements of Cash Flows table that was set forth in Part I, Item 1, of the Form 10-Q for the quarterly period ended October 31, 2000 that the Company filed with the Commission on December 15, 2000. The following table restates the Consolidated Statements of Cash Flows table in its entirety. 2 CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Cumulative From November 2, For the Three Months Ended 1995 (Date of October 31, Inception) to ---------------------------------------- to October 31, 2000 1999 2000 ---------------- ---------------- ---------------- Cash Flows From Operating Activities: Net loss $ (1,144,207) $ (1,118,772) $(22,960,932) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 21,026 21,237 231,703 Reduction of notes receivable - common stock in exchange for services rendered -- 9,508 423,882 Common stock issued for services rendered 411,250 -- 1,651,978 Stock options and warrants issued for services rendered -- -- 3,102,024 Preferred stock issued for services rendered -- -- 100 Founders shares transferred for services rendered -- -- 353,506 Changes in operating assets and liabilities: Miscellaneous receivables -- 107,236 27,873 Other current assets (153,004) 26,757 (255,752) Accounts payable and accrued liabilities 221,764 59,726 2,234,082 Other, net -- -- 110,317 ------------ ------------ ------------ Net Cash Used in Operating Activities (643,171) (894,308) (15,081,219) Cash Flows From Investing Activities: Purchase of property and equipment (473,034) -- (1,146,988) Costs incurred for patents (57,347) -- (326,846) Change in restricted cash -- -- (5,595) Purchase of short-term investments (13,735,738) (7,838) (17,702,001) Change in deposits 27,842 (23,161) 29,961 Change in notes receivable - common stock -- -- (4,118) Change in due from related parties -- -- (2,255,197) Other, net -- -- 89,683 ------------ ------------ ------------ Net Cash Used in Investing Activities (14,238,277) (30,999) (21,321,101) Cash Flows From Financing Activities: Proceeds from issuance of long-term debt -- -- 993,149 Repayment of long-term debt (2,245) (387,876) (963,021) Change in due to related parties -- -- 154,541 Proceeds from issuance of common stock, net 23,605,925 15,000 48,268,145 Purchase and retirement of common stock -- -- (119,066) ------------ ------------ ------------ Net Cash Provided By (Used In) Financing Activities 23,603,680 (372,876) 48,333,748 Effect of Exchange Rates on Cash (11,564) 8,360 (15,855) ------------ ------------ ------------ Net Increase (Decrease) in Cash and Cash Equivalents 8,710,668 (1,289,823) 11,915,573 Cash and Cash Equivalents, Beginning of Period 3,204,905 5,633,201 -- ------------ ------------ ------------ Cash and Cash Equivalents, End of Period $ 11,915,573 $ 4,343,378 $ 11,915,573 ============ ============ ============
3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, we have duly caused this amendment to be signed on our behalf by the undersigned. DATE: December 18, 2000 GENEREX BIOTECHNOLOGY CORPORATION By: /s/ E. Mark Perri ------------------------------------ E. Mark Perri Chairman and Chief Financial Officer 4 -----END PRIVACY-ENHANCED MESSAGE-----